Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 915
- Registration Number
- NCT00566501
- Locations
- 🇺🇸
Apex Research Institute, Santa Ana, California, United States
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT00548587
- Locations
- 🇺🇸
Beloit Clinic, SC, Beloit, Wisconsin, United States
🇬🇧Royal Brompton Hospital, London, United Kingdom
Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Drug: E6201 0.005%Drug: E6201 0.01%Drug: E6201 0.03%Drug: Placebo
- First Posted Date
- 2007-10-05
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00539929
Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT00525590
- Locations
- 🇺🇸
University of Arizona / University Medical Center, Tucson, Arizona, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Weill Medical College Department of Neurological Surgery, New York, New York, United States
An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy
- Conditions
- Diabetic Neuropathy
- Interventions
- Drug: E2007 (2 mg)Drug: E2007 (4 mg)Drug: PlaceboDrug: E2007 (6 mg)Drug: E2007 (8 mg)
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 352
- Registration Number
- NCT00505284
- Locations
- 🇺🇸
Dr. Richard Blonsky, Chicago, Illinois, United States
A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2009-02-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00499499
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
Neural Correlates In Mild Alzheimer's Disease
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT00477659
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1467
- Registration Number
- NCT00478205
- Locations
- 🇺🇸
MedTrials, Inc., Hickory, North Carolina, United States
A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 583
- Registration Number
- NCT00477295
A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation
- Conditions
- Vertigo
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT00474409
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, Beijing, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
🇨🇳Shanghai Renji Hospital, Shanghai, Shanghai, China